ArticleCureus2025
Early Diagnosis of Male Breast Cancer: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male breast cancer (MBC) is a rare neoplasm, and this rarity underscores the critical importance of awareness and appropriate screening. This study presents a case of male breast cancer (MBC) in a 64-year-old patient to enhance understanding of this rare and frequently underdiagnosed neoplasm. A 64-year-old man presented with a palpable mass in the left breast. Imaging revealed bilateral gynecomastia and a highly suspicious 4.3-cm Breast Imaging Reporting and Data System (BI-RADS) 5 nodule with nipple retraction. Biopsy confirmed histologic grade III invasive ductal carcinoma. Immunohistochemistry showed positivity for hormone receptors (Estrogen Receptor (ER) 90%, Progesterone Receptor (PR) 50%) and was negative for Human Epidermal Growth Factor Receptor 2 (HER2). Following left mastectomy, the patient experienced postoperative complications, including a contralateral hematoma and a persistent seroma. Oncotype diagnosis (DX) testing indicated a low chemotherapy benefit, leading to adjuvant therapy with tamoxifen. Pathologic tumor stage pT1c and pathologic nodal status pN0, confirmed by sentinel lymph node biopsy, indicated early-stage disease. The complexity of MBC underscores the critical importance of early diagnosis. The prompt detection of the suspicious mass, culminating in effective early-stage treatment, proved crucial to this patient's favorable prognosis, in contrast to the common trend of delayed diagnoses and their less promising outcomes. Accordingly, strengthening public awareness and professional training is essential to optimize management and improve outcomes in men with breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.